Venus Medtech (Hangzhou) Inc 2024 SR
The report highlights Venus Medtech's 2024 ESG performance, focusing on its leadership in minimally invasive heart valve interventions. Key achievements include the approval of the VenusA-Deluxe system and the successful US clinical trial of Venus P-Valve. The company maintained a robust quality management system with ISO 13485 and MDSAP certifications. Environmentally, the Group achieved its 2024 targets, including Zero-Waste Factory certification and significant reductions in hazardous waste. Socially, it emphasized talent development, achieving a 93.3% employee training rate, and actively contributed to industry standards and community welfare.
Company: Venus Medtech (Hangzhou) Inc
Sector: Health Care
Country: China
Year: 2024
Type: SR
Pages: 62
Venus Medtech (Hangzhou) Inc
ESG Report
The report highlights Venus Medtech's 2024 ESG performance, focusing on its leadership in minimally invasive heart valve interventions. Key achievements include the approval of the VenusA-Deluxe system and the successful US clinical trial of Venus P-Valve. The company maintained a robust quality management system with ISO 13485 and MDSAP certifications. Environmentally, the Group achieved its 2024 targets, including Zero-Waste Factory certification and significant reductions in hazardous waste. Socially, it emphasized talent development, achieving a 93.3% employee training rate, and actively contributed to industry standards and community welfare.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Mar 28, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees